The aims of this study were two-fold: 1) using [18F]THK5317-PET, to evaluate the presence and regional distribution of tau pathology in vivo in a cohort of AD patients; and 2) to examine the regional distribution of tau pathology in relation to hypometabolism and amyloid-beta deposition in vivo. Here, MAPT is linked to Alzheimer disease.